Monopar Therapeutics Stock (NASDAQ:MNPR)


OwnershipFinancialsChart

Previous Close

$4.85

52W Range

$1.37 - $8.65

50D Avg

$3.35

200D Avg

$3.23

Market Cap

$16.02M

Avg Vol (3M)

$824.86K

Beta

1.26

Div Yield

-

MNPR Company Profile


Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Dec 19, 2019

Website

MNPR Performance


MNPR Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-8.83M$-10.54M$-9.13M
Net Income$-8.40M$-10.49M$-9.08M
EBITDA$-8.83M$-10.54M$-9.13M
Basic EPS$-0.61$-0.83$-0.73
Diluted EPS$-0.61$-0.83$-0.73

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ENOBRenovaro Biosciences Inc.
PMVPPMV Pharmaceuticals, Inc.
MLYSMineralys Therapeutics, Inc.
SCPHscPharmaceuticals Inc.
KTTAPasithea Therapeutics Corp.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ACXPAcurx Pharmaceuticals, Inc.
SCPSScopus BioPharma Inc.
ANTXAN2 Therapeutics, Inc.
PHVSPharvaris N.V.
RZLTRezolute, Inc.
DMACDiaMedica Therapeutics Inc.
CADLCandel Therapeutics, Inc.
PEPGPepGen Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG